Naglazyme and condition aggravated Patient Reports February 11, 2012

Naglazyme Side Effects Report #5412401-3
Naglazyme side effect was reported by a Health Professional from UNITED STATES on July 25, 2007. Female patient, child 7 years of age, weighting 46.96 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme. After drug was administered, patient experienced the following side effects: abdominal pain , activated partial thromboplastin time prolonged, aortic valve incompetence, carpal tunnel syndrome , condition aggravated, disease recurrence, gastrointestinal haemorrhage, haematochezia, headache . Naglazyme dosage: 1 MG/KG; QW; IV. During the same period patient was treated with METHYLPHENIDATE, PREDNISONE, LANSOPRAZOLE, CALCIUM CARBONATE, DIPHENHYDRAMINE. Patient was hospitalized. Patient recovered.

Naglazyme Side Effects Report #5586061-5
Naglazyme side effect was reported by a Physician from BRAZIL on Dec 20, 2007. Male patient, child 7 years of age, weighting 32.19 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme. After drug was administered, patient experienced the following side effects: clonus, condition aggravated, disease progression, gait disturbance, hyperreflexia, hypotonia, muscle spasticity, muscular weakness, off label use. Naglazyme dosage: 1.5 ML; QM;INTH; 15 MG; X1; IV. Patient recovered.

Naglazyme Side Effects Report #5613391-0
Naglazyme side effect was reported by a Physician from BRAZIL on Jan 11, 2008. Male patient, child 7 years of age, weighting 32.19 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme. After drug was administered, patient experienced the following side effects: abasia, central nervous system lesion, clonus, condition aggravated, csf protein increased, hyperreflexia, hypotonia, meningeal disorder, muscle spasticity. Naglazyme dosage: 1.5 ML;QM;INTH, 15 MG;X1;IV. Patient recovered.

Naglazyme Side Effects Report #5663681-0
Naglazyme side effect was reported by a Physician from BRAZIL on Feb 22, 2008. Male patient, child 7 years of age, weighting 32.19 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme. After drug was administered, patient experienced the following side effects: condition aggravated, diffuse axonal injury, gait disturbance, hypotonia, intervertebral disc disorder, muscle spasticity, oxygen saturation decreased, pyramidal tract syndrome. Naglazyme dosage: 1.5 ML;QM;INTH;15 MG;X1;IV. Patient recovered.


Naglazyme Side Effects Report #5796870-5
Naglazyme side effect was reported by a Physician from BRAZIL on Mar 26, 2008. Male patient, child 7 years of age, weighting 32.19 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme. After drug was administered, patient experienced the following side effects: condition aggravated, disease progression, gait disturbance, hypotonia, muscle spasticity, muscular weakness, nuclear magnetic resonance imaging brain abnormal, oxygen saturation decreased. Naglazyme dosage: 1.5 ML QM INTH; 15 MG X1 IV; 15 MG X1 IV; 1.5 ML X1 INTH; 15 MG X1 IV; 1 ML/KG QW IV. Patient recovered.

Naglazyme Side Effects Report #5946388-1
Naglazyme side effect was reported by a Physician from BRAZIL on Oct 23, 2008. Male patient, 18 years of age, weighting 55.12 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme. After drug was administered, patient experienced the following side effects: cardiac failure, condition aggravated, fluid overload, lobar pneumonia, pneumonia bacterial, pulmonary hypertension . Naglazyme dosage: 25 MG;QW;IVDRP. During the same period patient was treated with CETRIRIZINE. Patient was hospitalized. Patient recovered.

Naglazyme Side Effects Report #6123836-8
Naglazyme side effect was reported by a Physician from BRAZIL on Mar 02, 2009. Male patient, 18 years of age, weighting 55.12 lb, was diagnosed with mucopolysaccharidosis vi and was treated with Naglazyme. After drug was administered, patient experienced the following side effects: cardiac failure congestive, condition aggravated, endotracheal intubation complication, incorrect dose administered, lobar pneumonia, pneumonia bacterial, pulmonary hypertension . Naglazyme dosage: 25 MG;QW; IVDRP. During the same period patient was treated with CETIRIZINE. Patient was hospitalized. Patient died on 03/02/2009.